Abstract The T cell co-stimulatory molecule OX40 and its cognate ligand OX40L have attracted broad research interest as a therapeutic target in T cell-mediated diseases. Accumulating preclinical evidence highlights the therapeutic efficacy of both agonist and blockade of the OX40eOX40L interaction. Despite this progress, many questions about the immuno-modulator roles of OX40 on T cell function remain unanswered. In this review we summarize the impact of the OX40eOX40L interaction on T cell subsets, including Th1, Th2, Th9, Th17, Th22, Treg, Tfh, and CD8 þ T cells, to gain a comprehensive understanding of anti-OX40 mAb-based therapies. The potential therapeutic application of the OX40 eOX40L interaction in autoimmunity diseases and cancer immunotherapy are further discussed; OX40 eOX40L blockade may ameliorate autoantigen-specific T cell responses and reduce immune activity in autoimmunity diseases. We also explore the rationale of targeting OX40eOX40L interactions in cancer immunotherapy. Ligation of OX40 with targeted agonist anti-OX40 mAbs conveys activating signals to T cells. When combined with other therapeutic treatments, such as anti-PD-1 or anti-CTLA-4 blockade, cytokines, chemotherapy, or radiotherapy, the anti-tumor activity of agonist anti-OX40 treatment will be further enhanced. These data collectively suggest great potential for OX40-mediated therapies.
Introduction
The immune system is finely-tuned with various highly differentiated immune cells and organs working together. As one of the major types of lymphocytes, T cells play essential roles in different stages of immune responses. Naïve T cells can quickly proliferate and differentiate into heterogeneous effector T cells after encountering antigens through particular cytokineenvironment stimulation. T cells are classified into CD4 þ T cells and CD8 þ T cells according to the glycoprotein types on their membrane surface. CD4 þ T cells, which are also called Th (T helper) cells, can differentiate into different subsets according to the cytokine profiles 1 . The widely studied subsets of CD4 þ T cells are Th1, Th2, Th9, Th17, Th22, Treg (regulatory T cells), and Tfh (follicular helper T cells) 1 . CD8 þ T cells, known as cytotoxic T lymphocytes, play important roles in immune defense against intracellular pathogens or infected cells. They engage and kill their target through several mechanisms, such as secreting cytokines such as tumor necrosis factora (TNF-a) and interferon-g (INF-g), releasing cytotoxic granules such as perforin and granzymes, and initiating FAS/FASL interaction. In addition to antigen stimulation through T cell receptors (TCR) and cytokine receptors, T cell activation also requires costimulatory molecular signals, such as constitutive CD27 or CD28 and inductive glucocorticoid-induced tumor necrosis factor receptor (GITR), and induced costimulatory molecules (ICOS) such as OX40 or 4-1BB 2 . Among those costimulatory molecules, OX40 is widely studied for its beneficial functions. Ligation OX40 signals with agonist anti-OX40 mAbs to convey activating signals to T cells, resulting in cytokine production, survival, expansion, and homeostasis of effector or memory T cells 3, 4 . OX40 is a member of the tumor necrosis factor receptor (TNFR) family, and it is also known as CD134 or TNFRSF4 4 . OX40 was first discovered on the surface of activated rat CD4 þ T cells in 1987.
Subsequent studies revealed that OX40 was expressed on both activated CD4 þ and CD8 þ T cells, neutrophils, and nature killer (NK) cells. OX40 has important co-stimulatory functions during T cell activation, mediating the survival and expansion of both CD4 þ and CD8 þ T cells in multiple animal models of autoimmunity, infectious disease, and cancer 5 . OX40 is also involved in controlling effector and memory T cell responses 4 . The mechanism by which OX40eOX40L signaling affects T cell function is complicated. Under certain conditions OX40 can strongly promote the induction of Th1, Th2, and Th9 cells, and under other conditions it can inhibit the generation of forkhead box p3 (Foxp3) Tregs 6 . Previous studies showed that OX40eOX40L signals can augment the immune response in T cells subsets through NF-kB, mitogen-activated protein kinase (MAPK), nuclear factor of activated T cells (NFAT), and BCL-2/XL-dependent anti-apoptotic pathways 7, 8 . These signaling pathways jointly contribute to the expression of pro-survival molecules and elevated cytokine production and augment the generation of both effector and memory T cell subsets 5 . Some reports focusing on the immunity role of OX40eOX40L signals on T cell biology considered the CD4 þ T cells as a whole 9 , leaving details of the OX40 influence on different T cell subsets neglected. Here in this review we first discuss the biology of OX40 and OX4OL and then present the detailed impact of OX40eOX40L signals on T cell subsets, including Th1, Th2, Th9, Th17, Th22, Treg, Tfh, and CD8 þ T cells, to provide a comprehensive understanding of its biology.
As a crucial T cell activation stimulator, either activation or blockade of OX40eOX40L signals can yield therapeutic efficacy. On one hand, blocking the OX40eOX40L pathway using OX40 or OX40L binding agents seems to inhibit autoreactive T cells and ameliorate autoimmunity disease, as in experimental autoimmune encephalomyelitis (EAE) models 8 . On the other hand, augmentation of OX40 signaling using OX40 agonist antibodies appears to enhance T cell-mediated anti-tumor immunity, contributing to tumor regression and prolonged survival. Here, OX40 agonists may increase T cell infiltration into tumors and enhance antitumor immune responses in conventional CD4 þ and CD8 þ T cells, thus improving survival rates in several preclinical cancer models, including B16 melanoma, Lewis lung carcinoma, colon cancer, breast cancer and 4T-1 breast cancer 10, 11 . Therefore, agonists of the OX40eOX40L pathway potentially can be adopted for cancer immunotherapy.
The biology of OX40 and OX40L
OX40 is a type 1 transmembrane glycoprotein composed of about 275 amino acids with three full cysteine-rich domains (CRDs) and a partial C-terminal CRDs 7 . The apparent molecular weight of OX40 is 50 kDa 5 . OX40, along with other TNFRSF members such as 4-1BB, CD27, CD30, and CD40, are T cell costimulatory molecules acting at different stages to modulate and control the immune response 6 . Unlike other constitutive T cell costimulatory receptors, such as CD28 and CD27, OX40 is not expressed on naïve T cells. OX40 is transiently induced by signaling following TCR engagement after antigen (Ag) recognition, peaking 48e72 h in activated T cells, including activated CD4 þ and CD8 þ T cells, as well as in neutrophils, natural killer cells (NK) and natural killer T cells (NKTs) 5 . The only exception is that OX40 is constitutive in mouse FOXP3
þ Treg cells. Many factors are involved in the kinetics of OX40 expression, including the cytokine milieu, the persistence of antigen, the inflammatory environment, and the influence of other co-stimulation pathways 5 . OX40-deficient T cells might normally proliferate and differentiate into effector T cells at 2e3 days after TCR engagement, but they showed notable reduction of survival after 12e13 days 12, 13 . That is, OX40 signaling may not affect the initial activation phase of T cells, but may play an essential role in maintaining late proliferation and survival in the T cell effector phase.
The ligand for OX40 (OX40L, also known as CD252), is also a member of the TNFR superfamily. OX40L is a type II glycoprotein with a 23-amino-acid cytoplasmic tail and a 133-amino-acid extracellular domain 7 . Murine OX40L can stimulate both human and mouse T cells; however, human OX40L can only stimulate human T cells 14 . OX40L is mainly expressed on activated antigenpresenting cells (APCs), such as dendritic cells (DCs), activated B cells, and macrophages. The types of cells that can be induced to express OX40L is much broader. Apart from APCs, OX40L also expressed on hematopoietic cells such as activated NK cells, mast cells or the responding CD4 þ T cells, and non-hematopoietic cells, such as endothelial cells or smooth muscle cells (summarized in Table 1 ) 4 , which provides the foundation for the two-step OX40eOX40L costimulation model (Fig. 1 ).
More specifically, the first step of OX40eOX40L signaling is the interaction between OX40 and OX40L after 2e3 days, when activated T cells bind to professional APCs, mainly DCs, since OX40L expression on the APC surface is inducible 1e3 days following initial antigen encounter. After that, the OX40-expressing activated T cells can encounter other OX40L-expressing cells during the effector phase after leaving the initial DCs. For example, OX40L expressed by CD4 þ T cells can also bind to OX40 on other CD4 þ T cells to enhance T cell survival 15 . OX40L þ B cells 16 , OX40L þ NK cells, OX40L þ mast cells 17 and OX40L þ endothelial cells can interact with OX40 þ -activated T cells to support T-cell function during the effector phase, which may result in multi-channel activation of T cells.
Effect of the OX40eOX40L interaction on different T cell subsets
As for the impact of the OX40eOX40L interaction on T cell subsets, Table 2 displays a brief summary and is also illustrated in Fig. 2 (IL-2), granulocyte-macrophage colony-stimulating factor (GM-CSF) and lymphotoxin 1 . Th1 cells are mainly implicated in cell-mediated antiviral and antimicrobial immunity to intracellular pathogens. As a matter of fact, the effect of Th1 cells on immunology is pleiotropic and the multitude of functions of Th1 is expanding. An excessive Th1 response will promote immunopathology and exacerbate autoimmunity by enhancing the production of pathogenic autoantibodies. However, deficiency in Th1 function would be associated with immunodeficiency. T cell activity and humoral immunity  Rodent malaria  19  Triggering larger memory Th1 and Tfh CD4 T cell  Plasmodium infections  20  Promoting CD4 T cell proliferation and survival  Graves' disease  21  Inducing splenic CD4 T . It also has been demonstrated that in the absence of adjuvant, OX40eOX40L interaction is capable of inducing a Th2 response, while in the presence of adjuvants both Th1 and Th2 responses are augmented. In an OX40L-deficient murine model of allergic asthma, Arestides et al. 57 found that blockade of OX40eOX40L signaling failed to support potent CD4 T cell responses, and the levels of allergen-induced Th1 as well as Th2 cytokines were significantly reduced. Thus, OX40 appears to be involved in a variety of mechanisms to control the priming of Th2 and Th1 responses, which appears dependent on the experimental conditions adopted. And engagement of OX40 with OX40L may deliver a strong co-stimulatory signal to newly activated effector T-cells and enhance both Th1 and Th2 responses 7 . While further studies proved that OX40eOX40L interactions exerted critical costimulatory effects on the Th1-mediated immune response and contributed to immunopathology in a variety of animal models 58 including experimental inflammatory bowel disease 59 , EAE 60 , rheumatoid arthritis (RA) 61 , colitis 62 and graft-versus-hostdisease. Blockade of OX40eOX40L interactions ameliorated these Th1-specific immune diseases. Using a myelin oligodendrocyte glycoprotein peptide (MOG)-induced EAE murine model, Ndhlovu, et al. 60 showed that the severity of EAE was either aggravated or alleviated depending on the expression of OX40L. OX40L-deficient mice or wild-type mice treated with anti-OX40L mAb (MGP-34) showed reduced clinical manifestations of EAE coupled with a reduction in Th1 cytokine production, including IFN-g and IL-2 60 . Conversely, transgenic overexpression of OX40L in mice lead to a greater severity of EAE with significantly elevated levels of IL-2, IL-6, and IFN-g 60 . Although these altered Th1 cytokine responses may have resulted from the inability of differentiation of both Th1 and Th2 effectors; noteworthy, however, is the recognition that EAE is usually regarded as a Th1-mediated disease and OX40eOX40L interactions were indeed involved in the Th1-mediated immune responses.
OX40 promotes generation and maintenance of Th2
Th2 cells are recognized for the secretion of IL-4, IL-5 and IL-13. Th2 cells are typically involved in immunity defense against extracellular pathogens and multi-cellular parasites, allergies and atopic illnesses 1, 63 . Th2 cells can exert anti-inflammatory ability by suppressing cell-mediated or Th1-mediated inflammation, since IL-4 possesses strong suppression of Th1 cell generation even in the presence of IFN-g. However, Th2 cells also play a role in several humorally-associated autoimmune diseases, in that aberrant IL-4 expression can induce activation of autoreactive B cells and thereby promote tissue inflammation and immunopathology.
Under neutral conditions the OX40eOX40L interaction preferentially promotes CD4 þ T cells to differentiate into Th2 effector cells through enhanced calcium/nuclear factor-activated T cell (NFATc) signals and up-regulated IL-4 production. A major role for the OX40eOX40L interaction in Th2-mediated allergic asthma 64 and Leishmania infection murine models has been substantiated 65 . An impaired ability to generate a Th2 response in an OX40-deficient murine asthma model has also been demonstrated, and was characterized by high levels of immunoglobulin E, IL-5 and IL-4 due to a reduced number of antigen-specific memory T cells, thus resulting in diminished lung inflammation and attenuated airway hyperreactivity 64 . On the other hand, Hoshino et al. 28 demonstrated a critical contribution of OX40L to the development of Th2-mediated experimental leishmaniasis and pulmonary inflammation. In an OX40L-deficient murine asthma model, all asthmatic responses including increased mucus production, accumulation of eosinophils, and high levels of Th2 cytokines were greatly diminished 28 . Administration of the neutralizing anti-OX40L mAb to wild-type asthmatic mice also abolished the induction of asthmatic responses during the sensitization period, indicating a pathogenic role of OX40L in differentiation of Th2 cells and in the pathway of Th2 polarization in vivo 28 . In accordance with several reports, in the absence of OX40eOX40L signals Th2 cells are impaired in clonal expansion resulting in a quite low level of memory T cells, suggesting that the OX40eOX40L interaction was indispensable in Th2 cell differentiation and Th2 polarization 66, 67 . What's more, the OX40eOX40L interaction was also indispensable in Th2 memory T cell generation and memory recall responses by sustaining expression of the antiapoptotic members of BCL-2 family, such as BCL-2, BCL-XL, or BFL1 66,67 .
OX40 favors Th9 differentiation through a non-canonical NF-kB pathway
Th9 cells, preferentially producing IL-9, are a novel CD4 þ T cell subset in the immune system with proinflammatory functions OX40-mediated Th9 cell enhancement has repercussions in vivo, including contributions to antitumor immunity or regulation of immunopathology in allergic lung and ocular inflammation 67 . In an allergic murine model, injection of agonist anti-OX40 antibody induced Th9 cell-dependent allergic airway inflammation and increased hyper-proliferation of mucin-producing cells in the airway epithelium 67 . There was an absence of any IL-9 enhancement in OX40L-deficient T cells, indicating the specific stimulation through the OX40eOX40L pathway.
In addition, Th9 cells induced by OX40 costimulation showed very high expression of IL-9 without expression of Th2 or Th17 cytokines, such as IL-10, which seemed to be distinct from Th9 cells without OX40 ligation 68 . Subsequent study revealed that the promotion of Th9 through OX40eOX40L signals didn't depend on PU.1, which was a key transcriptional regulator for the induction of Th9, but instead through tumor necrosis factor receptor-associated factor (TRAF) adaptor molecules, particularly TRAF6, which activated an NF-kB transcription factor complex and triggered a wide array of downstream biological functions 68 . OX40 costimulation could still increase IL-9-producing T cell differentiation under repression of the canonical NF-kB pathway, while mice lacking the non-canonical NF-kB subunit p52 were unresponsive to OX40 L 68 . Although OX40eOX40L signals can activate both the canonical and non-canonical NF-kB pathway, OX40 may act through the non-canonical NF-kB pathway to favor the potentiation of Th9 differentiation.
OX40 modulates the survival and function of Th17
Th17 cells are a newly emerged effector T helper cell subset. They can reinforce certain aspects of the adaptive immunity system such as host defense and tissue repair responses. They also can induce local tissue inflammation and promote autoimmune tissue injury via the secretion IL-17 family cytokines (mainly IL17). IL-17 signals can contribute to activation of innate immune cells, enhancement of B cell responses, recruitment of neutrophils, upregulation of proinflammatory mediators such as TNF-a, IL-1b or intercellular adhesion molecule 1 (ICAM-1) 1 . In addition to IL-17, Th17 cells can also secrete IL-21, IL-22, IL-25 1 . Th17 cells also possess anti-inflammatory ability through the production of the potent anti-inflammatory cytokines IFN-g and IL-10, thereby attenuating inflammation and pathology.
Accumulated evidence suggests that OX40 is a crucial costimulatory molecule involved in modulating the survival and function of Th17 cell 27 . In a mouse model of destructive arthritis deficient in IL-1 receptor, the authors showed that IL-17 did not induce OX40 expression, while activation of T cells through OX40 ligation enhanced IL-17 production, and blocking the OX40eOX40L pathway efficiently repressed the development of inflammatory peripheral arthritis, which could be at least partially linked to a significant reduction of IL-17 from Th17 cells in the peripheral synovial joints 69 . In an ovalbumin-induced uveitis model, Zhang, et al. 31 demonstrated that OX40-activating antibody significantly augmented the transfer of OX40-stimulated lymphocytes and elicited a more severe ocular inflammation in vivo, while an IL-17-neutralizing antibody attenuated OX40-mediated uveitis.
However, other studies also reported completely opposite results, with ligation of OX40 with OX40L on human T cells inhibiting IL-17 production, which was mediated through upregulation of IFN-g and IL-4, both of which are reported to inhibit the production of IL-17 70 . Moreover, OX40L still suppressed IL-17 production even in the presence of IL-23, which is a potent stimulator of IL-17 and differentiation factor for Th17 cells 70 . Therefore, the OX40eOX40L pathway plays a crucial role for enhancing the elaboration of Th17 cells, which may be partially dependent on the conditions.
Limited studies of the effect of OX40 on Th22
Th22 cells play a complicated role in inflammatory and autoimmune disease. Th22 cells produce predominantly IL-22 cytokine 71, 72 ; IL-22 seems to possess both pathogenic and protective effects according to environmental cues 71 . On one hand, IL-22 can promote inflammatory and autoimmune conditions in psoriasis, rheumatoid arthritis, Crohn's disease, and atopic dermatitis patients, suggesting its pathogenic role. On the other hand, IL-22
The costimulatory molecule OX40 in T-cell-mediated immunitywas down-regulated in the serum of patients with sarcoidosis and systemic lupus erythematosus 71 Many studies have explored the possibility that OX40eOX40L signals might have any impact on Tfh development and GC responses. OX40eOX40L signals have been found to promote expression of CXCR5 mRNA in activated mouse T cells in vitro. Soluble OX40L treatment increased the expression of several Tfhassociated molecules on T cells in lupus patients in vitro, including CXCR5, BCL-6 and IL-21. These studies also showed that OX40eOX40L interactions promoted CD4 T cells to accumulate at the T/B border and in B cell follicles in murine models 73 . There was a reduction of antibody production in OX40L-transgenic mice and mice lacking OX40 or OX40 L 73 . Based on those findings, it was concluded that OX40eOX40L signals indeed exert an effect on the maintenance of the Tfh function.
Using a vaccinia virus (VacV) infection murine model, Tahiliani et al. 34 showed that the number of Tfh cells was about 70% fewer in OX40-deficient mice compared to WT mice on Day 8e15 after VacV infection. A similar decrease was also found in the level of VacV-specific IgG Abs. This study also demonstrated that OX40eOX40L interactions were involved in maintaining the Tfh and GC Tfh pool after the Tfh phenotype was initially acquired. So whether OX40 is expressed on transitional Tfh cells or on mature Tfh cells, it always can play a strong role to maximize the Tfh response. OX40eOX40L interactions were found to cooperate with ICOSeICOSL interactions to maintain the Tfh response and amplify the ongoing Ab response at a late stage after infection 34 . Since OX40 was co-expressed with ICOS on both transitional and mature Tfh cells, it may be active in controlling Tfh cells at the same time.
In another study, OX40eOX40L signals contributed to an aberrant Tfh cell response in human systemic lupus erythematosus (SLE) 33 . OX40eOX40L signals promoted the expression of multiple Tfh-related molecules including CXCR5, IL-21 and CD40L in both naive and memory Tfh cells, and subsequently increased the generation of CXCR5
þ Tfh cells while downregulating the transcription repressor PR domain zinc finger protein 1 (PRDM1) which inhibits Tfh generation 33 . OX40LeOX40 signals were sufficient to render both naive and memory Tfh cells to become efficient B cell helpers, mainly mediated by TCR signal enhancement. One of the hallmarks of autoimmune diseases like SLE is autoreactive antibody production. This may suggest that the pathogenic contribution of Tfh cells in human SLE is via the OX40LeOX40 pathway, thus providing a rationale to target this pathway as a therapeutic modality.
However, there also are some contradictory results on the OX40eOX40L interaction in the regulation of Tfh cell responses. This study showed that the absence of OX40 signals did not affect Tfh differentiation, antibody generation, or even the CXCR5 expression 74 . Furthermore, Boettler et al. 32 showed that agonistic anti-OX40 mAb suppressed the expression of Bcl-6 while enhancing the expression of the Tfh-specific molecule BLIMP-1. As for the dual roles of OX40, one possible reason is that OX40 signals may collaborate with other factors to regulate Tfh differentiation, such as the microenvironment, the APCs, and Th cells themselves.
OX40 mainly antagonizes Treg-mediated suppression
To prevent autoreactivity, immune responses need to be properly controlled, which is partially dependent on the suppressive ability of Treg cells 75 . Treg cells are characterized by the expression of FOXP3, CD4, and CD25, and they are composed of two major subtypes, natural thymic derived Tregs (nTregs) and inducible Tregs (iTregs) post thymic maturation. The most commonly associated cytokines with Tregs are transforming growth factor-b (TGF-b) and IL-10. Generally, Treg cells are immunosuppressive and responsible for maintaining tolerance to self-antigens. Treg cells are also known to act as immunoregulators in many inflammatory and autoimmune disease by modulating antiinflammatory cytokines secretion 75 . In physiological immune responses, OX40 supports the survival and proliferation of activated CD4 þ T cells. It has been proposed that the potent costimulatory effect of OX40 is due to the blocking of the inhibitory activity of Tregs, although it could also be explained by the stimulatory effect on effector T cells in enhancing their resistant to suppression. Over last half-decade evidence has accumulated that OX40 signals are critical for controlling the function of FOXP3 . In addition to antagonizing inducible Treg generation, some studies revealed that OX40 also blocks natural Treg activity in certain situations 40 . Voo et al. 41 developed an anti-human OX40 agonistic mouse mAb that could promote effector CD4 þ and CD8 þ T cell proliferation while blocking natural Treg-suppressive function. However, Vu et al. 44 pointed out that OX40 stimulation did not significantly affect naturally arising CD4 þ
FOXP3
þ Tregs, but strongly antagonized the induction of new inducible FOXP3 þ Tregs from T effector cells.
Ligation of OX40 on the FOXP3 þ Treg cells abrogated their ability to suppress T effector cell proliferation, IFN-g production, and T effector cell-mediated allograft rejection. Triggering the OX40eOX40L interaction has also been proven to shut down the generation of IL-10-producing type 1 Tregs (Tr1) 43 , turn off FOXP3 þ Treg proliferation 44 , and inhibit TGF-b-and antigendriven conversion of naive CD4
. Valzasina et al. 40 found that agonist anti-OX40 mAb could abrogate Treg-mediated suppression of T-cell proliferation, and restored IL-2 gene transcription, cytokine production, and effector T cell proliferation in a model of graft versus host disease in vivo. Many studies have tried to identify the mechanisms by which OX40 costimulation suppresses Foxp3 expression and iTreg induction 8 . 40 did not observe differences in Treg cell number in the OX40-deficient mice described by Takeda et al. 39 They speculated that it was possibly obscured by the genetic background difference or environmental factors. OX40-deficient mice only showed a reduced number of Treg cells in their early life, implying that OX40 is either augmented or unnecessary in the homeostasis of Treg cells 39, 77 . 
Therapeutic benefit of OX40 in autoimmunity disease
Autoimmune disease is typically characterized by autoantibodies reactive against self-antigens due to the failure of the immune system to maintain self-tolerance against autoantigen. There are some well-known autoimmune diseases with high morbidity due to poorly understood pathogenesis. These include experimental autoimmune encephalomyelitis (EAE), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA), colitis, autoimmune experimental uveitis (AEU), type 1 diabetes mellitus, and multiple sclerosis (MS). Due to the pivotal role of T cells in controlling the immune response and costimulatory effect of OX40eOX40L interaction with T cells, targeting the OX40eOX40L interaction might ameliorate the autoantigen-specific T-cell responses. Therefore, experiments have been conducted to verify whether targeting the OX40eOX40L interaction by blockade of OX40 or OX40L had the therapeutic benefit for autoimmune diseases, including EAE, SLE, RA, colitis, AEU, type 1 diabetes mellitus, MS, graft-versushost disease (GVHD) and inflammatory bowel disease (IBD). Table 3 summarizes the effect of the OX40eOX40L interaction on several diseases. Overall, it shows that OX40 is upregulated at the sites of autoimmunity and correlates with disease severity. More specifically, there is no significant increased expression of OX40 in peripheral blood in localized diseases such as colitis, while a typical increase of peripheral OX40 þ CD4 þ T cells can be detected in more systemic conditions like SLE. OX40eOX40L blockade in vivo generally ameliorates autoimmunity, mainly by preventing migration, moderating T cell polarization, altering cytokine production, and preventing proliferation of active CD4 þ T cells 8 . Below we discuss the role of the OX40eOX40L interaction on EAE, SLE, and RA. 104 . MS is an autoimmune disorder characterized by variable pathological manifestations, including destruction of the myelin sheath, demyelinating plaques and axonal damage. There are several well studied EAE models and they are induced by different myelin-derived antigens: proteolipid protein (PLP)-induced EAE, myelin basic protein (MBP)-induced EAE, myelin oligodendrocyte glycoprotein (MOG)-induced EAE, and adoptively transferred EAE model. They play a crucial role in testing novel treatments for modulating the course of MS 105 . The possible therapeutic benefit of OX40 to autoimmune disease was first found in an EAE rat model, as both OX40 and OX40L are expressed on the surface of CNS cells in EAE mice; autoantigen-specific CD4 þ T cells from CNS had a significantly higher level of OX40 than those from peripheral blood. OX40 or OX40L deficiency can potentially reduce the ongoing signs of EAE. OX40L-deficient mice showed decreased clinical manifestations of actively induced EAE and decreased production of proinflammatory cytokines IFN-g, IL-2, and IL-6, which was mainly due to impaired APC capacity and abortive T cell priming 60 . In contrast, transgenic mice expressing OX40L developed a greater severity of EAE despite a delayed onset, with a markedly enhanced T cell response to protein antigen 60 . To further verify the therapeutic effect of the OX40eOX40L interaction blockade on the development of EAE, Nohara et al. 80 used PLP 139e151 peptide to build the active EAE model and an adoptively transferred EAE model, and treated those mice with various doses of neutralizing OX40L mAb (RM134L). RM134L treatment ameliorated the clinical signs of EAE in a dosedependent manner in both actively induced EAE and the adoptively transferred EAE model, thus indicating a substantial contribution of OX40 L 87 . In this study RM134L treatment greatly inhibited the accumulation of OX40-expressing CD4 þ T cells and the migration of pathogenic T cells into the CNS, but had little effect on the proliferation of IFN-g producing Th1 cells in DLN 80 . In another study Weinberg et al. 82 also reported an improvement in clinical signs of EAE by blocking OX40eOX40L engagement. The blockade of the OX40eOX40L interaction was achieved by administration of a soluble human OX40 immunoglobulin fusion protein with the ability to bind to murine OX-40L. OX40-blockade in mice inhibited T cell proliferation by 50%e 70%, resulting in a marked reduction in the severity of EAE and quicker recovery from EAE disease. However, the frequency and severity of relapses was not improved, suggesting that the effect may be short-lived 82 . As adoptive transfer of wild-type donor T cells to OX40L-deficient mice efficiently transferred EAE disease, while OX40L-deficient donor T cells failed to transfer EAE disease to wild-type recipient mice, this suggested that OX40eOX40L interaction may be involved in the T cell priming process in the occurrence of EAE disease 60 .
OX40 expression may correlate with SLE severity
SLE is a chronic multisystem complex autoimmune disorder. It is characterized by pathogenic autoantibodies in association with the dysfunction of the cellular immune, humoral immune and complement system 106 . The etiological cause of SLE is still incompletely understood, while the pathogenesis is mainly owing to the formation of immune complexes and the loss of immune tolerance. The defective B cell suppression and excess T cell helper cells are clearly involved in these processes through complex interactions among T cells, B cells, and APCs 106 . To seek possible SLE biomarkers, Patschan et al. 84 analyzed the expression of CD70, CD80, CD86, CD137, CD137L, OX40, CD152, CD154 and ICOS of CD4 þ T cell populations in the peripheral blood of SLE patients. Among all these co-stimulatory markers, CD80, CD86, and OX40 showed obviously elevated levels compared to a healthy group, which also correlated with the systemic lupus erythematosus disease activity index (SLEDAI) 84 . This was consistent with the results reported by Farres et al. 85 They investigated the percentage of CD4 þ T cell expressing OX40 and serum OX40L levels in SLE patients with lupus nephritis (LN). They found that there was a significantly elevated percentage of OX40 expression CD4 þ T cells in SLE patients. The significantly increased percentage of OX40 expression CD4 þ T cells can also be found in SLE patients with LN. The same increase also can be noted in the serum OX40L levels. They suggested that OX40 expression CD4 þ T cells and serum OX40L levels are an indicator of disease activity in SLE 85 . Some studies also investigated the pathogenesis of SLE through the identification of genetic components 88 . Multiple predisposing genetic factors are implicated in SLE pathogenesis, including OX40L which showed genetic linkage with SLE and also acts as components of B cell pathways 107 . Cunninghame Graham et al. 107 pointed out OX40L as a lupus susceptibility gene, as they showed the upstream region of OX40L contained a single risk haplotype for SLE. An over-expressed haplotype is correlated with increased expression of OX40L, which may influence the functional consequences of T cell activation via OX40 and destabilize peripheral tolerance 107 . In another study it was found that the OX40eOX40L interaction is bidirectional. The reverse signaling pathway via OX40L may augment the B cell differentiation and hyperactivity to aggravate SLE pathology, which is in keeping with the hallmark of SLE disease, autoreactive antibody 88 . The frequency of blood active-phenotype Tfh cells is increased in active SLE patients. Jacquemin et al. 33 reported that OX40L could promote SLE disease through promoting a Tfh cell response. As Tfh cells were specialized for provision of help to B cells, there may be certain interactions between autoantibodyproducing B cells and pathogenic Tfh cells through the OX40eOX40L axis. The OX40L signals in SLE patients can induce the proliferation of Tfh cells from Th cells and assist them to become functional B cell helpers 33 . Although the role of the OX40eOX40L axis in SLE disease is widely investigated, the mechanisms of the OX40eOX40L axis involved in SLE patients still needs further study. In the future, OX40eOX40L blockade may developed into a possible therapeutic approach to ameliorate SLE disease and alleviate autoantibody production, like the wellcharacterized T cell activation pathway, CD28eCD80/CD86 interaction.
OX40 blockade may ameliorate RA development
RA is a symmetric poly-articular autoimmune disorder. It is characterized by joint pain and progressive damage to the synovial tissue, especially in the hands, feet, and wrist, and may eventually result in joint destruction and bone erosion 89 . Although the etiological cause of RA is not totally understood, T cell-mediated autoimmune responses are definitely involved in the pathogenesis of RA. Administration of either anti-T cell antibodies or immunosuppressive drug targeting to T cells was effective in suppression of the progression of established RA murine disease. Saijo et al. 89 found that either IL-1a-or IL-1b-deficient mice correlated with lower expression of OX40 and CD40L, and showed reduced incidence of RA, suggesting that those factors collectively contributed to the lower responsiveness of T cells. The existence of OX40L can be detected on activated synovial dendritic cells or macrophages in synovial tissue and inflamed joints from RA patients. Additionally, the expression of OX40 on infiltrating activated T cells could be enhanced by locally produced pro-inflammatory cytokines in RA synovium, such as TNF-a or IL-1b. Therefore, it is likely that OX40eOX40L signaling acts through cellular contact-dependent interaction between infiltrating activated T cells and their nearby APC cells in the RA synovium under the dysregulated pro-inflammatory cytokine environment in the rheumatoid synovium 89 . Yoshioka et al. 61 investigated the contribution of the OX40eOX40L interaction on the pathogenesis of RA by administration of a neutralizing anti-OX40L mAb to a type II collagen (CII)-induced arthritis (CIA) murine model. Interestingly, they found that administration of anti-OX40L mAb had the potential to ameliorate the severity of RA through suppression of the production of IFN-g and anti-CII IgG2a; however, it did not suppress the activation of CII-reactive T cells. They speculated that the OX40eOX40L interaction may exert its contribution in subsequent steps after CII-reactive T cell activation 61 . That is, OX40 may act as an accelerator, but not an initiator, in the pathological development of RA.
Jiang et al. 55 reported the pathogenic role of
þ T cells was found in both RA patients and CIA mice. Those CD4 þ CD28 e OX40 þ T cells showed high production of pro-inflammatory cytokines, including IFN-g, TNF-a and IL-4, which may be correlated with clinical pathological features of RA patients and CIA mice. Blockade of the OX40eOX40L interaction resulted in inhibition of proinflammatory cytokine production in vitro, and also ameliorated arthritis progression in vivo 55 . A similar therapeutic benefit of OX40eOX40L blockade was found in another study, which resulted from a significant reduction in IL-17 from Th17 cells in peripheral synovial joints 27 . This evidence suggested that the regulatory role of OX40eOX40L signaling in autoimmune arthritis, which may represent an effective approach for immunomodulatory therapy.
Rationale for targeting OX40eOX40L interactions in cancer immunotherapy
Cancer immunotherapy is an emerging cancer treatment that utilizes the immune system of the cancer host to destroy cancer cells. Many studies have demonstrated the rationale of targeting OX40eOX40L interactions in cancer immunotherapy, as ligation of OX40 signals can promote conventional (non-regulatory) CD4 þ and CD8
þ T cell survival, sustain anti-apoptotic protein expression like BCL-XL, BCL-2 and survivn, enhance cytokine production like IL-2, IL-4, IL-5 and IFN-g, boost effector tumor-specific T cell immune responses, and augment tumor-specific memory T cell generation following antigen challenge, as summarized in Fig. 3  4,10,11 . Therefore, OX40eOX40L interaction possesses potent immunological effects and fuels interest as a target to improve tumor immunotherapy, as summarized in Table 4 .
However, some studies have revealed that the antitumor activity of OX40 agonists may be altered according to the immunogenicity of different tumor types. More specifically, OX40 agonists are likely to enhance antitumor immunity against immunogenic tumors such as MCA303 sarcoma tumors, CT26 colon carcinoma tumors, or SM1 breast cancer 10 . However, they may have less immunological protection and be insufficient to induce tumor eradication with poorly immunogenic tumors, such as B16/F10 melanoma tumors 10 . Since poorly immunogenic tumors may not provide the priming required by OX40eXO40L signals. Novel combining strategies that employ OX40 agonists in conjunction with other therapeutic treatments have been widely investigated, including combining OX40 agonists with the immunotherapy checkpoint inhibitors PD-1 or CTLA-4, immunotherapy costimulatory molecules like 4-1BB, certain cytokines like IL-2 or IL-12, chemotherapy, or radiotherapy, as summarized in Table 4 .
OX40 agonists and combination immunotherapy
The well-known "checkpoint inhibitor" programmed cell death protein 1 (PD-1) and CTL-associated antigen 4 (CTLA-4) can curtail immune responses and attenuate anti-tumor immunity. Administration of antagonist monoclonal antibodies (mAbs) targeting PD-1 or CTLA-4 show substantial promise to boost T cells anti-tumor immunity. Pembrolizumab is the first anti-PD-1 mAb approved by the U. S. Food and Drug Administration (FDA) to treat advanced metastatic melanomas, neck squamous cell carcinoma and metastatic non-small cell lung cancer. Two another anti-PD-1 mAbs (nivolumab and cemiplimab), and three anti-PD-L1 mAbs (atezolizumab, avelumab, and durvalumab) are also approved by the FDA for cancer treatment. On the other hand, ipilimumab is the first anti-CTLA-4 mAb for the treatment of melanoma and renal cell carcinoma. Indeed, blockade of "checkpoint inhibitors" PD-1 or CTLA-4 has demonstrated improved survival in both preclinical and clinical trials. However, clinical results also revealed that blockade PD-1or CTLA-4 alone was insufficient to induce tumor eradication and only a subset of patients showed objective clinical responses. In order to overcome the therapeutic limitations of checkpoint blockade monotherapy, many investigators studied the combination immunotherapy. OX40 plays a co-stimulatory role in T cell activation, and if combined with PD-1or CTLA-4 blockade it is supposed to further overcome tumor immune tolerance and ultimately generate a robust therapeutic immune response, as summarized in Table 4 .
Indeed, combination of OX40 agonists with PD-1/PD-L1 blockade may have complementary immunological effects. As OX40eOX40L interaction can increase CD4 þ and CD8 þ T cells populations which express the PD-1 receptor, and enhance production of cytokines like IFN-g that can up-regulate PD-L1 expression within the tumor microenvironment. Guo et al. 108 demonstrated that a combination of PD-1 blockade and OX40 stimulation synergistically protects against poorly immunogenic ovarian tumor growth, whereas neither PD-1 blockade nor OX40 stimulation alone had an effect on tumor growth and ascites formation in an ID8 murine ovarian cancer model. However, combined anti-PD-1/anti-OX40 mAb treatment significantly increased the overall survival of mice and achieved 60% tumor-free mice. The combined treatment showed elevated ratios of both effector CD4 þ and CD8 þ T cells to Treg cells and myeloid-derived suppressor cells (MDSC), and elicitation of an antigen-specific CTL response owing to the formation of a local immunostimulatory microenvironment 108 . In another study, Messenheimer et al. 110 reported that timing and sequencing are crucial to optimize the therapeutic effect of PD-1 blockade combined with anti-OX40. Anti-OX40 treatment can result in a delayed tumor progression in a preclinical oncogene-driven mammary cancer model which is refractory to PD-1 blockade. While a significant reduction in survival and tumor control was obtained with concurrent combination of anti-OX40 and anti-PD-1 blockade, suggesting that PD-1 blockade may provide an adverse effect on anti-OX40-induced therapy. Otherwise, augmented therapeutic efficacy was achieved by sequential and delaying anti-PD-1 administration, as it is more effective to give anti-PD-1 antibody after the initial T-cell boost generated by anti-OX40 110 . Although much evidence has shown that OX40 agonists are likely to synergize with PD-1 blockade, a better understanding of the immunological interplay between them is still needed.
CTLA-4 serves as a "checkpoint inhibitor" through competitively binding to B7-1 or B7-2 to downregulate the CD28 costimulatory pathway of T cells 11, 122 . The therapeutic anti-tumor benefit of anti-CTLA-4 blockade is limited, especially with poorly immunogenic tumors. As OX40 and CTLA-4 are both induced to express on CD4 þ and CD8 þ T cells after TCR stimulation, many studies have been conducted to determine if combined anti-OX40 stimulation and anti-CTLA-4 blockade would augment therapeutic responses and generate broader tumor immunotherapy. Indeed, compared to monotherapy with anti-OX40 or anti-CTLA-4, the combined anti-OX40/anti-CTLA-4 immunotherapy improved tumor regression and survival of tumor-bearing hosts in some tumor models, such as the moderately immunogenic MCA-205 sarcoma tumors or the poorly immunogenic TRAMP-C1 prostate tumors 11, 113 . Specifically, the therapeutic efficacy of dual anti-OX40/anti-CTLA-4 therapy is associated with decreased inhibitory effects of Treg cells and increased number and function of effector of CD4 þ and CD8 þ T cells. No therapeutic efficacy of combined therapy was obtained with pretreatment of CD4 and/or CD8 T cell depletion, suggesting a T cell-dependent mechanism 113 . Dual anti-OX40/anti-CTLA-4 therapy also resulted in enhanced cytokine production, including both Th1 (IL-2 and IFN-g) and Th2 (IL-4, IL-5, and IL-13) cytokines, which may help to drive potent polyclonal effector T cell responses 113 . Despite the enhanced anti-tumor ability that has been achieved with combination immunotherapy, tumor immunotherapy treatment still remains challenging because of tumor tolerance and poor immunogenicity 11, 112 .
Combination treatment of anti-OX40 with cytokines
The combination of cytokines with anti-OX40 immunotherapy is a popular strategy to enhance the immunogenicity of tumor cells and strengthen the antitumor immune response of the host. Many cytokines, such as IL-2, IL-12, IL-4, IL-15, TNF-a, or IFN-g, have shown potent immunomodulatory and antitumor effects in various preclinical studies 136, 137 . Among them, two cytokines are of particular interest, IL-2 and IL-12. IL-2 has been approved by the FDA to treat metastatic melanoma and metastatic renal cell carcinoma. However, despite its great antitumor potency, the application of IL-2 in the clinic still faces several unavoidable drawbacks, such as short half-life and high dose-related toxicities 136 . IL-12 can exert potent anticancer effects through both innate and adaptive immune responses. Therefore, IL-12 often synergizes with other therapeutic agents to achieve immunomodulatory benefits.
Redmond et al. 124 investigated the antitumor efficacy of a combination of anti-OX40 therapy with IL-2 therapy. According to their study, the expression of OX40 via TCR stimulation also required the involvement of the IL-2 receptor complex. Exogenous rIL-2 stimulation could strongly drive OX40 up-regulation in both murine and human T cells, suggesting the dual stimulation of TCR and IL-2R on OX40 expression, which was dependent upon the activation of JAK3 and the downstream transcription factors STAT3 and STAT5 124 . Using a murine pulmonary metastases (MCA205) tumor model they demonstrated that dual anti-OX40/ IL-2c immunotherapy can boost antitumor immunity with the help of effector CD4 and CD8 T cells. Negligible anti-tumor efficacy was obtained with depletion of either CD4 or CD8 T cell subsets prior to combination treatment. Combination treatment did not affect the function of Treg cells 124 . In another study, Ruby et al. 125 demonstrated the synergistic therapeutic efficacy of a combination of anti-OX40 and IL-12 in several different mouse tumor models, including a MCA205 tumor model, the TRAMP-C1 prostate tumor model, and the CT26 colon carcinoma. IL-12 signaling is quite critical for OX40-enhanced CD4 T cell survival, which is associated with STAT4-specific signaling.
Combining agonistic anti-OX40 mAb and RT
Radiotherapy (RT) is capable of anti-tumor effects and is widely used to treat loco-regional cancers, due to direct or indirect damage to the DNA of tumor cells 138 . RT is reported to induce bone marrow suppression and diminish T cell immunity, resulting in immunosuppressive effects to the cancer host. While RT can also be immunostimulatory by releasing tumor-associated antigens (TAAs), or increasing major histocompatibility complex (MHC) antigen expression to enhance tumor immunogenicity, this may depend on the radiation dose, type of tumor or irradiation site 138 . Many studies are underway to evaluate the efficacy of combining RT with agonistic anti-OX40 mAbs. Since RT mainly provides therapeutic applicability to local primary tumors, the agonistic anti-OX40 mAbs may act as an immunological partner to enhance the tumor eradication of RT, and meanwhile reduce its adverse effects.
Yokouchi et al. 119 evaluated the therapeutic effect of an agonistic anti-OX40 mAb with RT to treat lung cancer in mice. Compared to monotherapy, the anti-OX40 mAb in combination with RT treatment showed an improved cure rate and prolonged survival. None of mice were cured by RT alone or anti-OX40 mAb alone, while about 75% of the mice showed complete remission after treatment with the combined therapeutic schedule, suggesting greater tumor elimination efficacy. They also found that irradiation can help augment the proportion of OX40 þ
CD4
þ and OX40 þ CD8 þ T cells in draining lymph nodes (DLN), which may contribute to the synergistic effect of therapeutic immunity. Almost 89% of the mice treated with the anti-OX40 mAb in combination with RT remained disease free in a tumor rechallenge experiment, suggesting the durable tumor immunological memory of combination therapy 119 . Consistent with those findings, MJ Gough et al. 118 also confirmed the adjuvant role of anti-OX40 mAb to RT. They adopted the stereotactic body radiation therapy (SBRT) to a Lewis lung carcinoma (3LL)-established mouse cancer model. They found that RT initially decreased CD8 T cells within the radiation field compared to areas outside the radiation field, but later they gradually increased at the tumor site. Three treatments of RT can result in a significant increase in median survival but not durable tumor cures 118 . However, when RT was combined with a single dose of anti-OX40 mAb, not only the median survival was enhanced, tumor-free mice were obtained 118 . Anti-OX40 mAb facilitates the endogenous immune response to tumor cells mainly by increasing tumor antigen-specific CD8 T cell cytotoxic activity, which is definitely a valuable addition to RT.
In another study, Young et al. 120 identified optimal timing of combination immunotherapy with RT in advanced malignancies. They found that the optimal combination timing of anti-OX40 mAb and anti-CTLA4 mAb with RT was different, owing to their different immunotherapy mechanisms. CTLA4 is a checkpoint inhibitor, and pretreatment with anti-CTLA4 mAb showed superior tumor control. As for anti-OX40 agonist mAb, which is co-stimulatory agonist, it was optimally delivered during the tumor antigen-presentation period post-radiation. One day following radiation was suggested, which coincided with the upregulation time of OX40 on T cells 120 .
OX40 engagement and chemotherapy combination
Cancer chemotherapy routinely used in the clinic often causes lymphopenia and is easily deemed to be immunosuppressive 122 . However, studies also revealed that chemotherapy drugs, if given at proper dose, may facilitate anti-tumor potency, since the tumor cells killed by chemotherapy may be immunologically active and capable of leading to antigen cross-presentation and furtherly promote an adaptive tumor-specific immune response 139 . It is promising to combine RT with agonistic anti-OX40 mAbs treatment, since antigen presentation provided by RT-killed tumor cells can enhance subsequent effector T cell function, with participation of co-stimulatory molecules 140 . Cymerman et al. 122 reported the potent antitumor immunity of a combination of the anti-OX40 agonist mAbs (OX86) with cyclophosphamide (CTX) in well-established, poorly immunogenic B16 melanoma tumors. Approximately 75% of tumorbearing mice survived to Day 50 after being treated with a single dose of CTX on Day 6 followed by a single dose of OX86 on Day 7, owing to both direct antitumor effects and immuneenhancing properties. Neither CTX nor OX86 alone provided superior tumor protection. They also compared the efficacy of combination of CTX and OX86 with other immunotherapy monoclonal antibodies, such as anti-CD40 (FGK45), and anti-CTLA4 (9D9) 122 . They found that the combination of CTX with OX86 showed superior potency to any of the others in poorly immunogenic tumor models. Since CTX administration can induce partial destruction of the tumor, the antigen necessary to prime a tumor-specific response is available for OX40 to enhance the function of tumor-specific T cells, resulting in increased infiltration of CD8 þ T cells and decrease of Treg cells. Clinical trials of combination anti-OX40 with RT or CTX have been conducted in patients with chemotherapy-resistant prostate cancer to evaluate the toxicity on peripheral blood lymphocytes (PBL) 123 . Results showed that the degree of proliferation of PBL was not affected by the administration of anti-OX40 with RT or CTX, suggesting a manageable safety and great tolerability profile for combination therapy.
Anti-OX40 cancer therapy in human clinical trials
Currently there are six different OX40-targeted molecules used in clinical trials against cancers ( Table 5 ). The safety and efficacy of MEDI6469 (murine anti-OX40 agonist IgG1 antibody) is widely studied in patients with metastatic colorectal cancer (NCT02559024) and in head neck cancer (NCT02274155). Consistent with mouse tumor models, the combination strategies of agonist anti-OX40 antibody in clinic trails is currently ongoing in different tumors. As shown in Table 4 , there are three different kinds of ongoing combination strategies. The first one combined anti-OX40 costimulation with radiation therapy. A phase 2 trial (NCT01862900) is designed to test the safety profile and combination efficacy of MEDI6469 with SBRT in patients with metastatic breast cancer. An amplified and directed immune response is expected. The combination of anti-OX40 with co-stimulatory molecules is also being developed. A phase 1 trial (NCT02315066) is being conducted to assess the safety and maximum tolerated dose of PF-04518600, a fully human anti-OX40 agonist IgG2 antibody, alone or in combination with PF-05082566 (anti-4-1BB agonist antibody) in select advanced or metastatic carcinoma patients, and to select a recommended dose for a phase 2 study. In addition, another combination trials aims to analyze the potential of combining anti-OX40 co-stimulatory with anti-CTLA4 or anti-PDL1 co-inhibitory. For example, a phase 1 trial (NCT02410512) is proceeding to assess the safety and pharmacokinetics of MOXR0916 (humanized agonist anti-OX40 monoclonal antibody) with MPDL3280A (engineered anti-PD-L1 antibody) in a dose-escalation manner in patients with local or metastatic solid tumors. Project (NCT03241173) will explore the safety and efficacy of INCAGN01949 (fully human anti-OX40 agonist antibody) in combination with nivolumab or ipilimumab in advanced or metastatic malignancies. There are many ongoing or completed phase 1 or phase 2 clinical trials of anti-OX40, and although phase 3 and 4 clinical trials have not yet been reported, they invariably demonstrate great promise in the development of anti-OX40 immunotherapy.
Conclusive remarks and future prospects
Targeting the OX40eOX40L interaction for therapeutic purposes is highly promising, as both agonistic and blockade therapies have shown great efficacy. Results from combination therapies also displayed impressive therapeutic benefits for OX40, especially OX40 agonists in combination cancer immunotherapy, in both preclinical experiments and clinical trials. However, despite these advantages, there are significant limitations to our understanding of the full spectrum of functions of the OX40eOX40L interactions and their related therapies, such as optimal timing of administration, off-target effects, the need of concurrent treatment with other therapy, and the possibility of translating therapy owing to the differences in OX40 expression between mouse and humans. Timing of OX40 agonist or blockade administration may be critical to success since OX40eOX40L interactions are a series of timedependent checkpoints. Therefore, more investigation is urgently needed for the development of OX40-related drugs and therapies. 
